Heterocyclic inhibitors of ERK2 and uses thereof

A compound of general formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• A1 is CR10;
• A2 is CR11;
• T is selected from —C(R7)2—, C(O)—, —C(O)C(O)—, —C(O)NR7—, —C(O)NR7NR7—, —CO2—, —OC(O)—, —NR7CO2—, —O—, —NR7C(O)NR7—, OC(O)NR7—, —NR7NR7—, —NR7C(O)—, —S—, —SO—, —SO2 —NR7—, —SO2NR7—, —NR7SO2—, or —NR7SO2NR7—;
• m is selected from zero or one;
• R1 is selected from:
• (a) hydrogen, CN, halogen, R, N(R7)2, OR, or OH, wherein m is zero;
• or (b) hydrogen or R, wherein m is one;
• X is selected from —C(O)—, —C(O)NR7—, —NR7C(O)—, —NR7SO2—, —SO2NR7—, —S(O)—, or —SO2—;
• R2 is selected from —(CH2)yR5, —(CH2)yCH(R5)2, —(CH2)yCH(R8)(R5), —(CH2)yCH(R8)CH(R5)2, —N(R4)2, —NR4(CH2)yN(R4)2, —ON(R7)2, or —NR7OR6;
• y is 0-6;
• R6 selected from hydrogen or —R;
• each R is independently selected from an optionally substituted group selected from C1-6 aliphatic;
• 3-7 membered saturated, partially saturated, or aromatic monocyclic ring having zero to three heteroatoms independently selected from nitrogen, sulfur, or oxygen;
• or an 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having zero to four heteroatoms independently selected from nitrogen, sulfur, or oxygen;
• each R4 is independently selected from —R, —R7, —COR7, —CO2R, —CON(R7)2, —SO2R7, —(CH2)yR5, or —(CH2)yCH(R5)2;
• each R5 is independently selected from —R, —OR, —CO2R, —(CH2)yN(R7)2, —N(R7)2, —OR7, —SR7, —NR7C(O)R7, —NR7CON(R7)2, —C(O)N(R7)2, —SO2R7, —NR7SO2R7, —C(O)R7, —CN, or —SO2N(R7)2;
• each R7 is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group, or two R7 groups bound to the same nitrogen are taken together with the nitrogen to form a 3-7 membered heterocyclic ring having 0-2 heteroatoms in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;
• R8 is selected from —R, —(CH2)wOR7, —(CH2)wN(R4)2, or —(CH2)wSR7;
• each w is independently selected from 0-4;
• R9 is selected from hydrogen, a C1-6 aliphatic group, C(O)R7, C(O)OR7, or SO2R7;
• R10 and R3 are taken together to form an optionally substituted 5-7 membered saturated, partially saturated, or aromatic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• R11 is selected from R7, halogen, CN, NO2, OR7, SR7, N(R7)2, C(O)R7, or CO2R7;
• R12 is selected from R7, CN, NO2, halogen, N(R7)2, SR7, and OR7;
• and
• R13 is selected from R7, CN, NO2, halogen, N(R7)2, SR7, and OR7;
• provided that only one of R12 and R13 is a 3-7 membered saturated, partially saturated, or aromatic monocyclic ring having zero to three heteroatoms independently selected from nitrogen, sulfur, or oxygen;
• or an 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having zero to four heteroatoms independently selected from nitrogen, sulfur, or oxygen.